ELTROMBOPAG AS FIRST-LINE TREATMENT IN SEVERE APLASTIC ANEMIA: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

ELTROMBOPAG AS FIRST-LINE TREATMENT IN SEVERE APLASTIC ANEMIA: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Background: Eltrombopag actively promotes hematological response in association with immunosuppressive therapy (IST) as a first-line treatment for severe aplastic anemia (SAA). This study analyzes the cost-effectiveness of the combination of IST plus eltrombopag in the first line in SAA from the Bra...

Full description

Bibliographic Details
Main Authors: MA Salvino, C Bonfim, RT Calado, H Kim, JF Bertinato, P Scheinberg
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137921002108

Internet

http://www.sciencedirect.com/science/article/pii/S2531137921002108

Similar Items